Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Curvebeam AI Ltd. ( (AU:CVB) ) is now available.
CurveBeam AI Limited announced that it has ceased to be a substantial holder in itself following the release of all remaining ASX mandatory and voluntary escrow restrictions on its securities. This change reflects a shift in restrictions rather than any alteration in the underlying holders of securities. The announcement signifies a technical adjustment in the company’s shareholding status, which may impact its market positioning by potentially increasing the liquidity of its shares.
The most recent analyst rating on (AU:CVB) stock is a Buy with a A$0.18 price target. To see the full list of analyst forecasts on Curvebeam AI Ltd. stock, see the AU:CVB Stock Forecast page.
More about Curvebeam AI Ltd.
CurveBeam AI Limited is a company that develops, manufactures, and sells specialized medical imaging CT scanners. These scanners are coupled with AI SaaS-based clinical assessment solutions to support medical practitioners in managing musculoskeletal conditions. The company’s flagship product, the HiRise™ CT scanner, offers both weight-bearing and non-weight-bearing CT scans, providing advantages over traditional CT or MRI devices. CurveBeam AI operates with over 70 employees, with its corporate office and AI functions located in Melbourne, Australia, and its global operations headquarters in Hatfield, Pennsylvania, USA.
Average Trading Volume: 219,904
Technical Sentiment Signal: Buy
Current Market Cap: A$67.22M
See more insights into CVB stock on TipRanks’ Stock Analysis page.